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Two recent papers in Science reported the X-ray struc-
tures of the large, organizationally distinct animal and
fungal fatty acid synthases at 5 A˚. These new struc-
tural insights have unexpected implications for en-
zyme function for the other ‘‘iterative’’ and ‘‘assembly
line’’ megasynthases.
Five years ago, we saw the bacterial ribosome at 5 A˚ res-
olution [1–6]. Now, two landmark papers appearing re-
cently in Science present the first views of two fatty
acid synthases (FASs) at similar resolution, another im-
portant cellular macromolecular machine. Through a
complex catalytic mechanism involving decarboxylative
condensation, reduction,anddehydration activities,FAS
produces long-chain fatty acids from acetyl-CoA and
malonyl-CoA units. The protein in mammals is encoded
by a single gene, consists of seven catalytic domains,
and is functional as a homodimer (a2). In surprising con-
trast, analogous domains in fungi are distributed be-
tween two subunits, and a giant, structurally distinct
a6b6 barrel carries out the corresponding reactions, al-
though it releases its fatty acid product as the CoA ester
rather than the free acidas in the caseof mammalian FAS.
The breakthrough in the 3D structural elucidation of
animal FAS provides new insights and resolves the on-
going controversy over the structure of the enzyme.
The original model formulated in the 1980s envisioned
the two a-subunits of FAS oriented in an extended anti-
parallel arrangement in which a noncatalytic central core
stabilized the dimeric structure [7]. Stuart Smith and co-
workers proposed a revision of this view in accordance
with key biochemical findings and EM data highlighting
both intra-and interfunctional interactions of the sub-
units [8, 9]. Although the resolution of the current crystal
structure is insufficient to trace the complete backbone
of the individual subunits, the authors have fit atomic-
resolution structures of homologous individual bacterial
proteins into the electron density map of mammalian
FAS to reveal the location of most of the functional do-
mains. The model proposed by the authors depicts
two coiled subunits oriented head-to-head with paired,
centrally located KS domains stabilizing the dimer inclose agreement with the predictions of Smith. The X-
shaped model consists of a main body composed of
the ER and KS dimers and the pseudodimeric DH pairs,
while the monomeric KR and MT domains are located
peripherally at the top and bottom of the model, respec-
tively (Figure 1, left). The active sites of the two sets of
catalytic domains are oriented facing each of the two lat-
eral clefts in the structure, thus forming two asymmetric
reaction chambers. While ambiguities exist in the struc-
ture, for example, the key ACP and TE domains cannot
be clearly discerned, the crystal structure presents
a model that largely accommodates previous biochem-
ical findings.
As with the mammalian enzyme, EM analysis has pro-
vided a global view of fungal FAS. While the limits of res-
olution did not permit localization of individual domains,
it did allow general placement of the a and b subunits
within the a6b6 barrel [10, 11]. The X-ray structure has
now provided a sharper view in which active sites have
been approximated within most of the catalytic domains
in the enormous 230 3 260 A˚ cage-like superstructure
(Figure 1, right). Three sets of active sites face inward
within two identical reaction chambers. Each chamber
contains openings as large as 25 A˚, permitting sub-
strates and products to passively diffuse in and out as
their CoA esters. The structure determined at lower res-
olution (8 A˚) identified a potential attachment region for
the ACP located in the interior and accessible for inter-
actions among the domains of multiple subunits, which
agrees well with earlier biochemical studies [12].
Interestingly, the order of catalytic domains in animal
FAS parallels the bacterial type I modular, or ‘‘assembly
line,’’ polyketide synthases (PKSs) responsible for the
biosynthesis of a wide variety of macrolide and poly-
ether natural products as, for example, erythromycin
[13, 14]. The type I modular PKS model of intertwined di-
meric helices deduced by Peter Leadlay and Jim Staun-
ton has proved prescient in guiding thoughts not only
about modular PKSs, but also in unifying revision of
the long-held view of mammalian FAS head-to-tail di-
merization [14, 15]. Nonribosomal peptide synthetases
(NRPSs), a parallel universe of giant, modular enzymes
that make, for example, the precursors of penicillin
and vancomycin, are organized and function in an anal-
ogous manner [16, 17]. The synthetic potential of PKSs
and NRPSs is adroitly combined in Nature to synthesize
metabolites like epothilone and rapamycin [18].
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350Figure 1. Mammalian and Fungal FAS Structures
(Left) The mammalian FAS exists in a 9031803210 A˚ homodimeric X-shaped structure. The seven catalytic domains are the ketosynthase (KS),
malonyl/acetyl-transferase (MT), dehydrase (DH), enoyl-reductase (ER), ketoreductase (KR), acyl-carrier protein (ACP), and thioesterase (TE).
(Right) The fungal FAS exists as a 230 3260 A˚ a6b6 barrel. The a chain contains the ACP, KR, KS, and a phosphopantetheinyl transferase
(PPT) that activates its ACP by attachment of a pantetheine arm from CoA. The b chain harbors the acetyl-transferase (AT), ER, DH, and ma-
lonyl/palmitoyl-transferase (MPT) that loads malonate units and releases palmitate as its CoA ester. In the schematic domain organization, do-
mains shown in white were not resolved in the structure. The reaction chambers are marked with stars.The structures reported in the two papers by Ban and
coworkers are firsts for megasynthases, and they are
not only breakthroughs in their own right for under-
standing FAS enzymes, the paradigm member of this
class, but also for PKSs and NRPSs. The latter are of
intense interest as powerful synthetic engines to be
directed in combinatorial and chemoenzymatic ap-
proaches to make new products with improved biologi-
cal activities. Structural information about the spatial
organization of these multidomain systems has been
sorely lacking, and these papers will doubtless provide
a guide to both understanding their mechanisms of ac-
tion and engineering future experiments.
The structures held surprises too, like the widely
spaced active sites housed in the catalytic domains. In
light of the new structural details, the conventionally
taught, more globally static view of the ACP with its
18 A˚ pantetheine ‘‘swinging arm’’ reaching all the core
and ‘‘tailoring’’ active sites seems naive and is funda-
mentally inaccurate. The mammalian and fungal X-ray
structures show that both the ACP and its attached pan-
tetheine arm must traverse unexpectedly large dis-
tances to deliver the thioester bound intermediates to
the respective active sites to maintain processive syn-
thesis of the fatty acid. More than 45 reactions take
place without release of an intermediate in the elonga-
tion of acetate two carbons at a time to the C16 or C18
product. The authors show in each instance that the
ACP only delivers its acyl intermediate at close range:
a mechanistic advantage afforded by the great confor-
mational flexibility of the FAS, and particularly the ACP
itself, to allow the deep-seated active sites to be
reached. Although their positions in the X-ray structures
are ambiguous, the ACP domains would seem to be well
separated, yet biochemical data clearly show they can
participate in reactions occurring in both catalytic cham-bers. These reaction dynamics will have to be reconciled
with higher resolution structural information to under-
stand these observations.
Advances in structural understanding inevitably invite
more structural questions. The a and b subunits from
fungi are similar to the FAS subunits dedicated to form-
ing mycotoxins via secondary metabolism. For example,
the first committed step in the biosynthesis of the hepa-
tocarcinogenic mycotoxin aflatoxin B1 (in Aspergillus
spp.) is the production of a C6-fatty acid starter unit by
a pair of yeast-like FAS subunits. It has been proposed
that when interacting with its counterpart PKS, its over-
all oligomerization state exists as an a2b2g2 complex
[19]. This stoichiometry is distinct from the a6b6 arrange-
ment observed for the primary fungal FAS and more akin
to animal FAS and modular type I PKSs. Ultimately, it will
be interesting to know how this complex is organized.
The significance of the FAS structures is great. First,
as noted above, animal FAS is the paradigm of polydo-
main megasynthases and has direct relevance to PKSs
and NRPSs and their engineering. Second, FAS itself
has emerged as an important cancer, obesity, and infec-
tious disease drug target [20–22]. More highly resolved
views of each domain and active site in the context of
its partners will stimulate improved drug design ap-
proaches to inhibition of this important enzyme. Third,
and more broadly, these structures are of ‘‘iterative’’ en-
zymes that ingeniously reuse a single set of active sites
through many catalytic cycles to process intermediates
of increasing chain length and constantly changing
structure. The allied, if not certainly similar, type I ‘‘itera-
tive’’ PKSs, in addition, initiate reduction/dehydration
steps uniquely during chain elongation—a level of mo-
lecular ‘‘programming’’ that eludes understanding at
the moment. Examples of this can be seen in the biosyn-
thesis of lovastatin and enediyne anti-tumor antibiotics
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351as calicheamicin. In contrast, modular type I PKSs can
typically be ‘‘read’’ from the N to the C terminus in a read-
ily understandable way, as each domain in these syn-
thases carries out its reaction once and passes the
growing intermediate to the next module in the assem-
bly line on its way to the final thioesterase-mediated
step. All of these giant synthases/synthetases channel
substrates at high effective concentration among active
sites without release of intermediates through a large
number of synthetic steps. The two organizational plans,
either linear, ‘‘assembly line,’’ or circular, ‘‘iterative,’’ are
marvelously simple, yet chemically sophisticated.
Despite this recent advance, at the limit of about 5 A˚
resolution these X-ray structures inescapably leave frus-
tration that detailed mechanistic questions remain unre-
solved. Structure-based drug design efforts will have to
wait for higher resolution pictures of individual domains
or groups of them. Similarly, while the domain organiza-
tion of mammalian FAS is mirrored in modular type I
PKSs, the details of their organization are not identical
in ways that are hard to appreciate in the absence of
comparable PKS structures. As revealing and exciting
as these images are, these questions underscore even
more strongly the urgency and value of atomic-level res-
olution structures of the FAS, PKS, and NRPS enzymes.
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